RxDoctor Payments Data

Zadie Kenkare, MD

Internal Medicine · Clinton, CTNPI 1033281977

Payments from drug & device makers

$1,807in general payments, 2019–2025

Across 104 payments — averaging $17.38 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$306
  • Astellas Pharma US Inc$282
  • Novo Nordisk$219
  • Lilly USA, LLC$142
  • Currax Pharmaceuticals LLC$136
  • Pfizer$118
  • plus $604 from 16 others

What the payments were for

  • Food & beverage$1,75797%
  • Education$503%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,807 in reported general payments places this provider in the 80th percentile of 2,067 internal medicine providers in Connecticut.

See all internal medicine providers in Connecticut

Medicare billing

Part B allowed, 2024
$112,308
Medicare patients
216
Services billed
1,383

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide48$63,515
OzempicSemaglutide33$51,340
Repatha SureclickEvolocumab57$49,731
RybelsusSemaglutide26$45,646
MyrbetriqMirabegron24$20,231
EliquisApixaban18$18,588
FarxigaDapagliflozin Propanediol17$16,066
Praluent PenAlirocumab23$15,067
SynthroidLevothyroxine Sodium115$12,820
Rosuvastatin Calcium540$6,897
SymbicortBudesonide/Formoterol Fumarate18$5,285
Amlodipine Besylate516$3,545
Ezetimibe178$3,275
Levothyroxine Sodium287$3,255
Omeprazole109$2,545

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$219$96,98559 claims
Lilly USA, LLCMounjaro$142$63,51548 claims
AstraZenecaFarxiga, Symbicort$306$21,35135 claims
Astellas Pharma US IncMyrbetriq$282$20,23124 claims
PfizerEliquis$118$18,58818 claims
AbbVieSynthroid$104$12,820115 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 2,067 internal medicine providers in Connecticut.

Other internal medicine in Clinton

See the full list for Connecticut

Where these figures come from

Is this you, or does something look wrong? →